Literature DB >> 15742157

Long-term effects of IFN-gamma, IL-10, and TGF-beta-modulated dendritic cells on immune response in Lewis rats.

Rui-Sheng Duan1, Hans Link, Bao-Guo Xiao.   

Abstract

Increasing data have shown that IFN-gamma, IL-10, and TGF-beta-modulated dendritic cells (DC) provide a promising strategy in treatment of experimental allergic encephalomyelitis and experimental autoimmune myasthenia gravis through different manner. To explore the immune response status after long-term application of these cytokine-modulated-DC, Lewis rats were injected subcutaneously into naive DC and IFN-gamma, IL-10, and TGF-beta-modulated DC (i.e., IFN-gamma-DC, IL-10-DC, and TGF-beta-DC) at does of 1 x 10(6) cells/rat every month for continuous 18 months, respectively. No rats suffered from decreased vigor and activity as well as cachectic condition during 18-month observation, and no rats had body-weight loss after 18-month treatment. Exploratory laparectomy did not find any tumor in all rats. IL-10-DC and TGF-beta-DC resulted in lower nonspecific (Con A-induced) and antigen specific (ovalbumin-stimulated) spleen mononuclear cells proliferation, accompanied by lower levels of IFN-gamma, IL-10, and TNF-alpha. On the contrary, IFN-gamma-DC did not suppress cell proliferation and IFN-gamma and IL-10 production except only slightly decreased TNF-alpha levels. These results suggest that IFN-gamma-DC seems to be a more ideal candidate in the treatment of autoimmune diseases without suppressing immune response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15742157     DOI: 10.1007/s10875-005-0357-4

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  13 in total

Review 1.  Burnet oration: dendritic cells: multiple subtypes, multiple origins, multiple functions.

Authors:  K Shortman
Journal:  Immunol Cell Biol       Date:  2000-04       Impact factor: 5.126

Review 2.  Dendritic cell-based cancer immunotherapy.

Authors:  Edgar G Engleman
Journal:  Semin Oncol       Date:  2003-06       Impact factor: 4.929

Review 3.  The dendritic cell system and its role in immunogenicity.

Authors:  R M Steinman
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

4.  Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells.

Authors:  Francesca Fallarino; Carmine Vacca; Ciriana Orabona; Maria L Belladonna; Roberta Bianchi; Brendan Marshall; Derin B Keskin; Andrew L Mellor; Maria C Fioretti; Ursula Grohmann; Paolo Puccetti
Journal:  Int Immunol       Date:  2002-01       Impact factor: 4.823

Review 5.  Rat models as tool to develop new immunotherapies.

Authors:  H Link; B G Xiao
Journal:  Immunol Rev       Date:  2001-12       Impact factor: 12.988

6.  Transfer of dendritic cells (DC) ex vivo stimulated with interferon-gamma (IFN-gamma) down-modulates autoimmune diabetes in non-obese diabetic (NOD) mice.

Authors:  M Shinomiya; S M Fazle Akbar; H Shinomiya; M Onji
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

7.  Dendritic cells exposed in vitro to TGF-beta1 ameliorate experimental autoimmune myasthenia gravis.

Authors:  D Yarilin; R Duan; Y-M Huang; B-G Xiao
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

Review 8.  Dendritic cell vaccine design: strategies for eliciting peripheral tolerance as therapy of autoimmune diseases.

Authors:  Bao-Guo Xiao; Yu-Min Huang; Hans Link
Journal:  BioDrugs       Date:  2003       Impact factor: 5.807

9.  Therapeutic potential of IFN-gamma-modified dendritic cells in acute and chronic experimental allergic encephalomyelitis.

Authors:  Bao-Guo Xiao; Xing-Chen Wu; Jian-She Yang; Ling-Yun Xu; Xuan Liu; Yu-Min Huang; Borje Bjelke; Hans Link
Journal:  Int Immunol       Date:  2004-01       Impact factor: 4.823

10.  Induction of tolerance by IL-10-treated dendritic cells.

Authors:  K Steinbrink; M Wölfl; H Jonuleit; J Knop; A H Enk
Journal:  J Immunol       Date:  1997-11-15       Impact factor: 5.422

View more
  4 in total

1.  Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis.

Authors:  Matthew N Meriggioli; Jian Rong Sheng; Liangcheng Li; Bellur S Prabhakar
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

2.  Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis.

Authors:  Jian Rong Sheng; Liang Cheng Li; Balaji B Ganesh; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Clin Immunol       Date:  2008-05-27       Impact factor: 3.969

Review 3.  Research advancement in immunopathogenesis of myasthenia gravis.

Authors:  Sha Huang; Li-Ming Tan
Journal:  Neurosci Bull       Date:  2010-02       Impact factor: 5.203

4.  Exosomes derived from atorvastatin-modified bone marrow dendritic cells ameliorate experimental autoimmune myasthenia gravis by up-regulated levels of IDO/Treg and partly dependent on FasL/Fas pathway.

Authors:  Xiao-Li Li; Heng Li; Min Zhang; Hua Xu; Long-Tao Yue; Xin-Xin Zhang; Shan Wang; Cong-Cong Wang; Yan-Bin Li; Ying-Chun Dou; Rui-Sheng Duan
Journal:  J Neuroinflammation       Date:  2016-01-12       Impact factor: 8.322

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.